These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38916211)

  • 1.
    Muthusamy B; Berktas M; Li J; Thomas DS; Sun P; Taylor A; Pennell NA
    Future Oncol; 2024 Jun; ():1-14. PubMed ID: 38916211
    [No Abstract]   [Full Text] [Related]  

  • 2. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
    Kris MG; Mitsudomi T; Peters S
    Transl Lung Cancer Res; 2023 Apr; 12(4):824-836. PubMed ID: 37197636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA
    Zhang SS; Ou SI
    Lung Cancer (Auckl); 2022; 13():23-31. PubMed ID: 35506019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
    Wu YL; Tsuboi M; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS
    Future Oncol; 2021 Dec; 17(35):4827-4835. PubMed ID: 34723634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
    J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
    Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
    BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
    Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
    Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
    Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH
    Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
    Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
    J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
    Isla D; Felip E; Garrido P; Insa A; Majem M; Remon J; Trigo JM; de Castro J
    Clin Transl Oncol; 2023 Jan; 25(1):283-291. PubMed ID: 36168085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery.
    Ma W; Sheng Z; Niu Y; Yan B; Chen Y; Yang H; Li R
    Heliyon; 2023 Nov; 9(11):e20955. PubMed ID: 37920491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.
    Helland Å; Myklebust TÅ; Conte S; Frederiksen LE; Aarøe J; Enerly E
    Cancer Treat Res Commun; 2024; 38():100785. PubMed ID: 38190787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data.
    Nieva J; Reckamp KL; Potter D; Taylor A; Sun P
    Drugs Real World Outcomes; 2022 Sep; 9(3):333-345. PubMed ID: 35661118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
    Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.